Last 12 months
Inside the activity.
0 purchase rows · 83 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 9 |
| Jan 2026 | 0 | 3 |
| Feb 2026 | 0 | 2 |
| Mar 2026 | 0 | 17 |
| Apr 2026 | 0 | 8 |
| May 2026 | 0 | 9 |
| Jun 2026 | 0 | 8 |
| Jul 2026 | 0 | 9 |
| Aug 2026 | 0 | 4 |
| Sep 2026 | 0 | 8 |
| Oct 2026 | 0 | 2 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 03, 2017 Filed Jan 4, 2017 23:47 UTC |
SMITH SANDFORD DDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 4,032 | $4.96 Strike: $12.40 | $19,999.93 |
DisclosureSEC source: 0001061983-17-000009 · edgardoc.xml · derivative · entry 1 SMITH SANDFORD D · CIK 0001243004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,032 Underlying: Common Stock · 4,032 shares Expires 2027-01-03 F2 · price: This option was issued to the reporting person pursuant to the Cytokinetics 2004 Equity Incentive Plan in lieu of 50% of an annual retainer of $40,000.00 F1 · derivative.exercise_date: This option shall vest and become exercisable as to 4,032 shares divided into equal monthly installments such that the option shall be 100% vested on January 3, 2018. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 23:47 UTC |
Kaye Edward M. MDDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 8,064 | $4.96 Strike: $12.40 | $39,999.86 |
DisclosureSEC source: 0001061983-17-000007 · edgardoc.xml · derivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,064 Underlying: Common Stock · 8,064 shares Expires 2027-01-03 F2 · price: This option was issued to the reporting person pursuant to the Cytokinetics 2004 Equity Incentive Plan in lieu of an annual retainer of $40,000.00 F1 · derivative.exercise_date: This option shall vest and become exercisable as to 8,064 shares divided into equal monthly installments such that the option shall be 100% vested on January 3, 2018. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 23:47 UTC |
HENDERSON JOHN TDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 8,064 | $4.96 Strike: $12.40 | $39,999.86 |
DisclosureSEC source: 0001061983-17-000006 · edgardoc.xml · derivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,064 Underlying: Common Stock · 8,064 shares Expires 2027-01-03 F2 · price: This option was issued to the reporting person pursuant to the Cytokinetics 2004 Equity Incentive Plan in lieu of an annual retainer of $40,000.00. F1 · derivative.exercise_date: This option shall vest and become exercisable as to 8,064 shares divided into equal monthly installments such that the option shall be 100% vested on January 3, 2018. Read SEC document |
| December 29, 2016 Filed Dec 30, 2016 21:28 UTC |
Malik Fady IbrahamEVP Research & Development
|
SaleCommon Stock | 1,326 | $12.52 | $16,600.19 |
DisclosureSEC source: 0001061983-16-000061 · edgardoc.xml · nonDerivative · entry 4 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35 Read SEC document |
| December 28, 2016 Filed Dec 30, 2016 21:28 UTC |
Malik Fady IbrahamEVP Research & Development
|
SaleCommon Stock | 1,800 | $12.32 | $22,182.48 |
DisclosureSEC source: 0001061983-16-000061 · edgardoc.xml · nonDerivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,361 Read SEC document |
| December 28, 2016 Filed Dec 30, 2016 21:28 UTC |
Malik Fady IbrahamEVP Research & Development
|
SaleCommon Stock | 200 | $12.31 | $2,461.00 |
DisclosureSEC source: 0001061983-16-000061 · edgardoc.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,161 Read SEC document |
| December 28, 2016 Filed Dec 30, 2016 21:28 UTC |
Malik Fady IbrahamEVP Research & Development
|
SaleCommon Stock | 2,307 | $12.31 | $28,399.17 |
DisclosureSEC source: 0001061983-16-000061 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,361 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.